Cargando…

Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab

Elotuzumab is a humanized monoclonal antibody targeting the extracellular domain of signaling lymphocytic activation molecule F7 (SLAMF7) highly expressed in multiple myeloma cells. Upon binding to myeloma cells, elotuzumab exerts its cytotoxic effects through antibody-dependent cellular cytotoxicit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Einsele, Hermann, Schreder, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2016
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5026292/ https://www.ncbi.nlm.nih.gov/pubmed/27695618 http://dx.doi.org/10.1177/2040620716657993

Ejemplares similares

Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma
por: Friend, Reed, et al.
Publicado: (2017)

Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns
por: Danhof, Sophia, et al.
Publicado: (2021)

Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma
por: Campbell, Kerry S., et al.
Publicado: (2018)

Elotuzumab for the Treatment of Relapsed or Refractory Multiple Myeloma, with Special Reference to its Modes of Action and SLAMF7 Signaling
por: Taniwaki, Masafumi, et al.
Publicado: (2018)

Elotuzumab for the treatment of multiple myeloma
por: Wang, Yucai, et al.
Publicado: (2016)

Elotuzumab: The First Monoclonal Antibody for the Treatment of Multiple Myeloma
por: Fancher,(1,2), Karen M., et al.
Publicado: (2016)

P1025: A PILOT STUDY OF THE ANTI-SLAMF7 MONOCLONAL ANTIBODY, ELOTUZUMAB, IN PATIENTS WITH MYELOFIBROSIS.
por: Bose, Prithviraj, et al.
Publicado: (2023)

Elotuzumab for multiple myeloma
Publicado: (2022)

SLAMF7 as a Promising Immunotherapeutic Target in Multiple Myeloma Treatments
por: Chu, Emily, et al.
Publicado: (2023)

Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date
por: Weisel, Katja
Publicado: (2016)

Profile of elotuzumab and its potential in the treatment of multiple myeloma
por: Liu, Yi-Chang, et al.
Publicado: (2014)

P808: CONTROLLED FRATRICIDE TO AUGMENT ANTI-MYELOMA REACTIVITY OF SLAMF7 AND CD38 CAR T CELLS
por: Konetzki, Verena, et al.
Publicado: (2023)

Clinical impact of serum soluble SLAMF7 in multiple myeloma
por: Ishibashi, Mariko, et al.
Publicado: (2018)

Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab
por: Chen, Wei-Chih, et al.
Publicado: (2017)

Update on elotuzumab for the treatment of relapsed/refractory multiple myeloma: patients’ selection and perspective
por: Trudel, Sabrina, et al.
Publicado: (2019)

Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers
por: Hose, Dorothea, et al.
Publicado: (2020)

Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma
por: Zhou, Xiang, et al.
Publicado: (2020)

CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma
por: Prommersberger, Sabrina, et al.
Publicado: (2021)

Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study
por: Jagannath, Sundar, et al.
Publicado: (2018)

Overcoming Proteasome Inhibitor-Refractory Multiple Myeloma With Elotuzumab, Bortezomib, Nelfinavir, and Dexamethasone
por: Erath, Alexandra, et al.
Publicado: (2020)

Long-Term Disease Control by Pomalidomide-/Dexamethasone-Based Therapy in a Patient with Advanced Multiple Myeloma: A Case Report and Review of the Literature
por: Danhof, Sophia, et al.
Publicado: (2015)

A case of tumor lysis syndrome and acute renal failure associated with elotuzumab treatment in multiple myeloma
por: Atchison, Douglas K., et al.
Publicado: (2017)

Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma
por: Liu, Liping, et al.
Publicado: (2016)

Mechanisms of Action and Clinical Development of Elotuzumab
por: Ritchie, David, et al.
Publicado: (2017)

Population pharmacokinetic and exposure–response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma
por: Ide, Takafumi, et al.
Publicado: (2021)

Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin
por: Shimazu, Yutaka, et al.
Publicado: (2023)

Downregulation of Chemokine CCL20 Involved in Myeloma Cells Resistant to Elotuzumab and Lenalidomide
por: Wang, Huihan, et al.
Publicado: (2021)

Negative Regulation of Humoral Immunity Due to Interplay between the SLAMF1, SLAMF5, and SLAMF6 Receptors
por: Wang, Ninghai, et al.
Publicado: (2015)

Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis
por: Suzuki, K, et al.
Publicado: (2017)

Exploration of Artificial Intelligence Use with ARIES in Multiple Myeloma Research
por: Loda, Sophia, et al.
Publicado: (2019)

(11)C-Methionine-PET in Multiple Myeloma: Correlation with Clinical Parameters and Bone Marrow Involvement
por: Lapa, Constantin, et al.
Publicado: (2016)

CRISPR-Mediated Triple Knockout of SLAMF1, SLAMF5 and SLAMF6 Supports Positive Signaling Roles in NKT Cell Development
por: Huang, Bonnie, et al.
Publicado: (2016)

The efficacy of combination treatment with elotuzumab and lenalidomide is dependent on crosstalk between natural killer cells, monocytes and myeloma cells
por: Richardson, Kelden, et al.
Publicado: (2022)

Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study
por: Cella, David, et al.
Publicado: (2018)

Combinatorial targeting of multiple myeloma by complementing T cell engaging antibody fragments
por: Geis, Maria, et al.
Publicado: (2021)

Virotherapy, gene transfer and immunostimulatory monoclonal antibodies
por: Quetglas, José I., et al.
Publicado: (2012)

Finding the Right Heavy Chains for Immunostimulatory Antibodies
por: Boulard, Pierre, et al.
Publicado: (2022)

Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211
por: Usmani, S Z, et al.
Publicado: (2015)

BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice
por: Zhou, Xiang, et al.
Publicado: (2022)

SLAMF7 regulates the inflammatory response in macrophages during polymicrobial sepsis
por: Wu, Yongjian, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mft9gc8t97olgltb0d2547835q